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Abstract
High variability in patients’ changes in 6 minute walk distance (6MWD) over time has complicated clinical trials of treatment efficacy in
Duchenne muscular dystrophy (DMD). We assessed whether boys with DMD could be grouped into classes that shared similar ambulatory
function trajectories as measured by 6MWD. Ambulatory boys aged 5 years or older with genetically confirmed DMD who were enrolled in a
natural history study at 11 care centers throughout Italy were included. For each boy, standardized assessments of 6MWD were available at annual
intervals spanning 3 years. Trajectories of 6MWD vs. age and trajectories of 6MWD vs. time from enrollment were examined using latent class
analysis. A total of 96 boys were included. At enrollment, the mean age was 8.3 years (mean 6MWD: 374 meters). After accounting for age,
baseline 6MWD, and steroid use, four latent trajectory classes were identified as explaining 3-year 6MWD outcomes significantly better than a
single average trajectory. Patient trajectories of 6MWD change from enrollment were categorized as having fast decline (n = 25), moderate decline
(n = 19), stable function (n = 37), and improving function (n = 15) during the 3-year follow-up. After accounting for trajectory classes, the standard
deviation of variation in 6MWD was reduced by approximately 40%. The natural history of ambulatory function in DMD may be composed of
distinct trajectory classes. The extent to which trajectories are associated with novel and established prognostic factors warrants further study.
Reducing unexplained variation in patient outcomes could help to further improve DMD clinical trial design and analysis.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Approximately one in every 3500 male births is affected by
Duchenne muscular dystrophy (DMD), an X-linked disease
arising from mutations to the dystrophin gene [1]. Early signs
generally appear at 2–3 years of age, and include frequent
falls and developmental delay [2]. Ambulatory function may
improve in younger patients due to age-related growth and
development. However, disease progression eventually reverses
these gains with progressive impairment of motor function and
loss of ambulation by between 9 and 14 years on average,
depending on the steroid regimen used [3,4] and subsequent
progressive involvement of upper limb function [5,6].
Changes in ambulatory ability measured by the 6-minute
walk distance (6MWD) test have been characterized in several
longitudinal natural history studies [7–10], and this test has been
used as the primary functional outcome measure for clinical
trials of the first three disease modifying DMD treatments under
investigation (ataluren, drisapersen and eteplirsen). At the time
of reporting initial results from these trials, challenges were
apparent in using 6MWD to measure treatment effects [11,12].
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In particular, rates of change in 6MWD showed significantly
greater cross-patient variability than expected, resulting in
limited statistical power to measure treatment effects with
available sample sizes.
Variability in the rate of progression of 6MWD is known to
be influenced by age, baseline 6MWD, and steroid use [2].
Longitudinal studies of 6MWD over 12, 24 and 36 months have
identified a number of possible cut-off points that help to
identify different profiles of progression, such as baseline
6MWD ≥ 350 meters and age ≥ 7 years [7,13,14]. On average,
boys below the age of 7 have shown annual improvements on
the 6MWD, while boys above the age of 7 have shown annual
declines [7]. However, individual boys may show improving or
declining function on either side of this age threshold.
In addition to variability in rates of progression from boy to
boy, shorter-term, measurement-related variability has been
characterized across repeated 6MWD assessments within
individual boys. Although 6MWD is effort based, and can be
influenced by motivation, test–retest reliability is high, with
correlations exceeding 0.9. The variability in 6MWD that has
frustrated clinical trials is primarily due to high inter-patient
variability in rates of change rather than the smaller-scale, intra-
patient measurement noise. For this reason, there remains a
clear need for better characterizing the variability in 6MWD
rates of change.
To objectively characterize the natural history of 6MWD in
DMD, the present study sought to classify patients based on their
trajectories of ambulatory function over time. Classification
of patients based on disease trajectories has been used to
understand natural histories in a number of diseases, including
cardiovascular diseases and mental health conditions [15,16],
and has been used to identify associations between patient
outcomes and biomarkers [17] and to help interpret treatment
effects in randomized trials [18–21]. We applied latent trajectory
analysis to study the natural history of ambulatory function in
DMD, as measured by 6MWD, and explored whether trajectory
classes could help to further explain variation in disease
progression after accounting for age, steroid use and baseline
6MWD.
2. Methods
2.1. Patient selection and outcomes measurement
The patients and outcomes included in this study have been
previously described as part of an ongoing natural history
study of DMD [9,10,22]. Included boys were enrolled at 11
tertiary neuromuscular care centers in Italy between January
2008 and June 2010. Inclusion required boys to have genetically
confirmed DMD, to be aged 5 years or older, to be able to
walk independently for at least 75 meters, and to be free of
moderate or severe learning difficulties or behavioral problems.
All boys fulfilling these criteria at the study centers were
enrolled. The present study sample includes 96 boys with 3
years of annual 6MWD assessments conducted at the same
study center at intervals of 12 ± 3 months. 6MWD was assessed
at enrollment and annually according to the American Thoracic
Society guidelines [23], with the modification of having two
examiners (one recording time and distances and one staying
close to the patient for safety issues) [24]. The last follow-up
visit in the study sample was performed in August 2013.
Steroid use prior to and during follow-up was classified into
three categories: no steroids, intermittent steroids, and daily
steroids.
Only anonymous, de-identified data were analyzed in the
present study. Data collection was approved by the Ethical
Committees of all 11 of the participating centers. As the
assessments were already part of the clinical routine in all
centers, with the approval of the Ethics Committees, verbal
consent to record the anonymized data in a database was
obtained from the parents for the boys underage. All clinical
investigations were conducted according to the principles
expressed in the Declaration of Helsinki.
2.2. Statistical analysis
The goal of this study was to characterize variation in 6MWD
trajectories. A first step in characterizing variation is to measure
its magnitude. The magnitude of variation in 6MWD outcomes
has been widely reported in DMD, with standard deviations for
annual change ranging from 80 to 100 meters. A next step, taken
in this study, is to ask whether such a variable population might
be better understood as a mixture of several distinct groups.
Suppose, as a hypothetical example, that annual rates of change
in 6MWD exhibited a bimodal distribution across patients with
one peak around 50 meters of decline and another peak around
100 meters of decline. This distribution would suggest that the
population can be treated as a composite of two groups, and
that appropriately classifying patients (e.g., based on a cutoff
somewhere between 50 and 100 meters of decline) would
yield subgroups worthy of further characterization. In this
hypothetical example the classification can be based on a single
number (annual rate of decline).
Changes in ambulatory function in DMD, especially over the
3-year time period addressed in the current study, are complex
and can include periods of both improvement and decline. They
cannot be well characterized by a single number. For this
reason, the present study employed a statistical method, latent
class trajectory analysis, which extends the intuition applied in
the hypothetical example above to settings in which each
individual is characterized by multiple measurements over time.
Considering all measurements, the method asks whether there
are distinct peaks in the distribution across patients, i.e. clusters
of patients that share similar trajectories.
Latent class trajectory analysis was also used to model annual
6MWD outcomes up to and including the first visit reflecting a
loss of ambulation (defined as a 6MWD of zero meter). These
analyses assessed whether the observed trajectories of 6MWD
vs. age were adequately described by a single underlying mean
trajectory or, alternatively, by a mixture of two or more
underlying mean trajectories, with each mean trajectory
corresponding to a latent class [25–27]. Within each latent class,
mean 6MWD was modeled as a quadratic function of age, thus
allowing for periods of increasing and decreasing 6MWD.
Variation in 6MWD around the mean trajectory for each
individual was modeled using a subject-specific random
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intercept and independent Gaussian errors at each visit. Models
with one, two, three, etc., latent trajectory classes were fit to the
6MWD data using maximum likelihood and were compared in
terms of their unexplained variation in 6MWD. Sensitivity
analyses were conducted with 6MWD modeled as a more
flexible function of age (i.e. including cubic terms) and with
autoregressive error models.
Because adding latent trajectory classes to the model for
6MWD outcomes would necessarily improve the fit to the
data, thereby reducing unexplained variation, Akaike’s Information
Criterion (AIC) and the Bayesian Information Criterion (BIC)
were used for model selection [28,29]. These measures help
optimize the tradeoff between a model’s goodness of fit and its
complexity, as measured by the number of model parameters
governing the mean trajectory in each latent class. The number
of latent classes that minimizes the AIC and BIC provides a
description of the data that is parsimonious and better fitting
than models with fewer numbers of latent classes. After selecting
the appropriate number of classes using AIC and BIC, each
patient was assigned to the class that best matched their
individual trajectory. This assignment was made based on
posterior probabilities of class membership, which account for
the likelihood that an individual trajectory would occur in each
class and the relative sizes of each class. Patients were assigned
to the class for which they had the maximum posterior probability
of membership, i.e., that class to which they were most likely
to belong based on the fitted model. Confidence in these
assignments was assessed by averaging the assignment
probabilities across the patients within each class.
Because clinical trials of treatments for DMD typically
measure changes in function from the time of enrollment,
additional latent class trajectory analyses were conducted from
this perspective. In particular, within each latent class, mean
changes in 6MWD from the time of enrollment were modeled
as a linear function of age at enrollment, 6MWD at enrollment,
steroid use, and post-baseline visit time as a categorical variable
(with levels of 1, 2 and 3 years). Variation in change in 6MWD
around the mean was modeled using Gaussian errors with a
common variance. Models with subject-specific random effects
and autoregressive errors were also explored. AIC and BIC
were used to select the number of latent classes, and, based on
the selected model, patients were assigned and classified as
described above. For each group, patients were characterized
in terms of age, 6MWD at enrollment, and steroid use. These
analyses were repeated while including all 6MWD assessments
equal to zero meter following loss of ambulation (as opposed
to terminating the included data following the first visit with
loss of ambulation, as in the primary analyses). All analyses
were implemented using the lcmm package in R [27].
3. Results
3.1. Patient characteristics
Among the 96 boys included in the present study, age at
enrollment ranged from 5 to 17 years with a mean age of 8.3
years and a standard deviation (SD) of 2.1 years. Sixty eight
boys (71%) were aged 7 years or older. Mean 6MWD at
enrollment was 373.7 meters (SD 82.4). Nearly 65% had a
6MWD greater than or equal to 350 meters. Of the 96 patients
in the study, 92 (96%) were on a corticosteroid regimen: 42
received daily steroids and 50 received intermittent steroids.
Four patients were classified as having no steroids. A total of 24
boys lost ambulation during the study period: 3 by the end of
the first year, 16 by the end of the second year and 24 by the end
of the third year.
3.2. Classification of 6MWD trajectories vs. age
Individual patient trajectories of 6MWD vs. age exhibited
wide variation (Fig. 1). When a single mean trajectory of
6MWD vs. age was fit to these data, the residual, unexplained
variation in 6MWD had a standard deviation (SD) of 71.5
meters. A latent class model with four classes was identified as
the best fitting model, based on reduced AIC and BIC. This best
fitting four-class model reduced the residual variation in
6MWD to an SD of 43.5 meters. The residual variation
followed an approximate normal distribution (Fig. S1).
When patients were assigned to the four classes based on
maximum posterior probabilities, there were 8 patients assigned
to class 1, 22 assigned to class 2, 22 assigned to class 3, and 44
assigned to class 4 (Fig. 2). Average trajectories in the 4 classes
overlapped substantially at ages younger than 7 years, but they
separated along increasingly distinct trajectories with increasing
age. Among trajectories with observed loss of ambulation, the
first experience of 6MWD = 0 meter occurred at ages 8.9–10,
10.3–12.4, 13–14.4 and after 15 years, respectively, for patients
in classes 1–4 (Fig. 2). Age at loss of ambulation was not well
represented in the data for this last class; only one patient was
observed to lose ambulation in his late teens (at age 19 years), but
was much older than all other patients in the sample. (Repeating
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Fig. 1. Individual patient trajectories of 6MWD vs. age. Each point represents
a patient’s 6MWD, with lines connecting annual assessments from the same
individual patient.
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the analyses after excluding this patient did not substantially
change the results.) Steroid use was present in all classes.
However, all 4 of the patients without steroid use were assigned
to class 1. Steroids were used intermittently for 1 (12.5%), 9
(40.9%), 13 (59.1%) and 27 (61.4%) of the patients assigned to
classes one through four, respectively, with the remaining
patients receiving daily steroids.The assignment to classes based
on posterior probabilities could, on average, be made with high
confidence; the average posterior probability of being in the
assigned class was over 80% (Supplementary Table S1).
3.3. Classification of 6MWD trajectories vs. time from
enrollment
A second latent class analysis studied 6MWD trajectories as
a function of time from enrollment. By the end of the 3-year
study period, average 6MWD had decreased by 104.2 meters
from the time of enrollment, and a total of 24 patients had lost
ambulation. Individual patient trajectories varied substantially
around the mean trajectory (Fig. 3). A model with a single mean
trajectory for change in 6MWD, which was allowed to depend on
baseline age, 6MWD, and steroid use, had a residual standard
deviation of 95.4 meters across all post-baseline visits.
Alternative single-class models including indicators for baseline
Fig. 2. Predicted and observed trajectories of 6MWD vs. age. Solid black lines represent the predicted mean 6MWD trajectory in each class; gray lines represent
the individual patient trajectories assigned to each class.
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Fig. 3. Changes in 6MWD vs. time from enrollment. The solid black line
represents the mean change in 6MWD from enrollment at each of the 3
follow-up years; error bars represent ±one standard deviation. Gray lines
represent individual patient trajectories. Solid black points represent visits with
loss of ambulation (defined as 6MWD = 0 meter).
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age ≥ 7 years and baseline 6MWD ≥ 350 meters did not
substantially improve the model fit, nor did models including an
interaction between baseline 6MWD and visit number (residual
SD exceeded 90 meters in all cases). However, the addition of
latent classes improved model fit. Models with two and three
latent classes reduced the unexplained variation to 71 and 62
meters, respectively. The model with four latent classes was
identified as providing the most parsimonious description of
changes in 6MWD, based on minimization of BIC and AIC, and
after adjustment for baseline age, 6MWD, and steroid use. This
model had a residual standard deviation of 55.6 meters.
The four trajectory classes in the selected model exhibited
the following patterns (Fig. 4). In the first class, labeled as “fast
decline,” 6MWD declined at an average rate of approximately
117 meters per year. In the second class, labeled as “moderate
decline,” 6MWD declined at approximately 50 meters per year.
The third class has relatively “stable” mean 6MWD over the
3-year study period, with an average decline of approximately
10 meters after 3 years. In the final class, labeled
“improvement,” mean 6MWD increased by almost 100 meters
during the study period.
When patients were assigned to these classes based on
maximum posterior probabilities, there were 25 patients
classified as having “fast decline,” 19 patients classified as
“moderate decline,” 37 classified as “stable” and 15 classified as
having “improvement” (Table 1). The average posterior
probability of being in the assigned class was over 80% for each
class (Supplementary Table S2).
Average baseline characteristics differed among patients
assigned to these 4 trajectory classes (Table 1). Patients
assigned to the “improvement” class were the youngest, with a
mean age of 6.5 years and less than one third older than 7 years
at enrollment. In contrast, over 90% of the patients assigned to
the “fast decline” class were older than 7 years. Patients with
6MWD ≥ 350 meters at enrollment were present in all classes,
representing the minority in the “fast decline” class and the
large majority in the “improvement” class.
Assignments to classes based on both change in 6MWD vs.
age and change in 6MWD vs. time from enrollment provided
complementary descriptions of natural history, and are both
illustrated in Supplementary Fig. S2.
As a sensitivity analysis, model selection was repeated for an
analysis of all visits, including recurrent visits following loss of
ambulation (at which 6MWD = 0 meter). This analysis assessed
the extent to which unexplained variation may be reduced by
latent trajectory analysis in intent-to-treat analyses that
included all follow-up assessments. In this sensitivity analysis,
the single class model adjusting for baseline age, baseline
6MWD, and steroid use had a residual standard deviation of
102 meters. Adding up to 4 latent classes to this model
decreased both the BIC and AIC, and reduced the residual
standard deviation to 56 meters.
4. Discussion
In this retrospective analysis of DMD natural history data,
classes of boys who shared similar trajectories of ambulatory
function were detected. Accounting for these trajectory classes
explained significant variation in 6MWD, even after accounting
for age, steroid use and baseline 6MWD. Baseline 6MWD and
age exhibited expected associations with subsequent rates of
changes in 6MWD, with faster declining groups having lower
average 6MWD, higher average age and a higher proportion
aged 7 years or older, compared to groups with stable or
improving trajectories.
The degree to which trajectory classes reduced unexplained
variation in 6MWD has important implications for DMD clinical
trial design and analysis. Smaller sample sizes can shorten the
time and reduce the costs required for enrollment and
completion of a trial. Reduced variation in outcomes translates
into increased power and smaller sample size requirements. For
example, to detect a 30 meter treatment effect on change
in 6MWD, a proposed minimal important difference [30],
with 80% power, approximately 110 boys would be required with
SD = 56, and more than 310 boys would be required with
SD = 95. If a study design reduced variation to 75 meters,
approximately 50% of the way between 95 and 56 meters, a
sample size of 200 would be required. Enabling trials to achieve
adequate power with smaller numbers of patients would help
Table 1
Patient characteristics stratified by trajectory class (based on changes in 6MWD from enrollment).
Characteristics “Fast decline” “Moderate decline” “Stable” “Improvement”
N = 25 N = 19 N = 37 N = 15
Age at enrollment, years
Mean ± SD 9.5 ± 2.3 9.4 ± 1.8 7.4 ± 1.6 6.5 ± 1.0
Median (range) 9.4 (6.0, 17.0) 9.1 (6.1, 12.8) 7.7 (5.0, 11.3) 6.1 (5.0, 8.2)
Age ≥ 7 years, n (%) 23 (92.0) 17 (89.4) 24 (64.9) 4 (26.7)
6MWD at baseline, meters
Mean (SD) 300.1 ± 76.2 369.7 ± 56.0 412.7 ± 72.4 405.0 ± 62.3
6MWD ≥ 350 meters, n (%) 7 (28.0) 11 (57.9) 31 (83.8) 13 (86.7)
Age ≥ 7 years and 6MWD ≥ 350 meters, n (%) 7 (28.0) 11 (57.9) 21 (56.8) 4 (26.7)
Steroid use, n (%)
No steroids 3 (12.0) 0 (0.0) 1 (2.7) 0 (0.0)
Intermittent 10 (40.0) 10 (52.6) 21 (56.8) 9 (60.0)
Daily 12 (48.0) 9 (47.4) 15 (40.5) 6 (40.0)
SD = standard deviation.
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expand the diversity of treatments that could be investigated
across the DMD community at the same time.
Randomized trials of drug effects could reduce outcome
variation through enrichment of particular patient trajectories, or
by stratification or adjustment for baseline characteristics that
predict outcome trajectories. In addition to reducing variation in
outcomes, clinical trial design may seek to enrich for patients
whose trajectories of ambulatory function are thought to be most
modifiable by a particular study drug’s mechanism of action. All
of these considerations apply to both randomized trials and study
designs that include comparisons to natural history controls and
are particularly relevant to many of the ongoing or planned
clinical trials using exon skipping that target small numbers of
boys with specific subgroups of DMD mutations. The initial
clinical trials for exon skipping interventions are in the largest
sub-populations, and as the population sizes decrease, the
limited numbers of patients available to participate in these
studies may become prohibitive for placebo-controlled study
designs. It will therefore be important to identify and qualify
appropriate controls for prospective clinical study designs, and
for potential comparison to a control arm drawn from natural
history studies matched on characteristics that predict outcome
trajectories. These results provide a proof of concept, indicating
that latent class trajectory analysis can contribute to the
characterization of heterogeneous ambulatory outcomes in
DMD.The approach may also help characterize variation in rates
of change of non-ambulatory (e.g., pulmonary or cardiac)
outcomes in DMD, or surrogate markers (e.g., imaging of
skeletal muscle).
To the best of our knowledge, this is the first mathematically-
driven quantification of rates of DMD disease progression
using latent class methodology. However, observable
differences between groups of patients across a range of
outcome measures have previously been reported.
Translation of the trajectory classes identified in this study
into statistical tools for clinical trial design and analyses could be
further explored following two approaches. The first approach is
to identify baseline predictors of outcome trajectories. Beyond
baseline age, 6MWD, and steroid regimen, potential predictors
include other functional assessments (e.g., time to climb stairs,
0.0 0.5 1.0 1.5 2.0 2.5 3.0
-4
00
-2
00
0
20
0
Fast decline
Years from Enrollment
C
ha
ng
e 
in
 6
M
W
D
 (
m
)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
-4
00
-2
00
0
20
0
Moderate decline
Years from Enrollment
C
ha
ng
e 
in
 6
M
W
D
 (
m
)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
-4
00
-2
00
0
20
0
Stable
Years from Enrollment
C
ha
ng
e 
in
 6
M
W
D
 (
m
)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
-4
00
-2
00
0
20
0
Improvement
Years from Enrollment
C
ha
ng
e 
in
 6
M
W
D
 (
m
)
Fig. 4. Predicted and observed trajectories of 6MWD vs. time from enrollment. Solid colored lines represent the predicted mean 6MWD trajectory in each class;
gray lines represent the individual patient trajectories assigned to each class. Solid black points represent visits with loss of ambulation (defined as 6MWD = 0 meter).
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time to rise from supine and other components of the North Start
Ambulatory Assessment), height, weight, direct measures of
muscle strength, age at steroid initiation and dystrophin
genotype. Other possible predictors include genetic modifiers
[31,32], MRI measures of muscle composition [33,34], or other
biomarkers currently being investigated.The maximum extent to
which combinations of currently available measures can predict
ambulatory outcomes in DMD is an important topic for future
research. An accurate prediction model for trajectories of
ambulatory function would enable improved enrichment,
stratification, baseline adjustment, and matching in clinical trials
with randomized or natural history controls.
The second approach for utilizing the trajectories identified in
the present study is the direct application of latent class
trajectory analysis in the study of drug effects in DMD. Such
analyses have been used to explore drug effects in a number of
other therapeutic areas, and, in addition to reducing unexplained
variation, can identify potential treatment effect heterogeneity
across patients with different underlying trajectories [18–21].
Care must be taken in the interpretation of these analyses
because the latent classes are identified using post-baseline or
post-randomization outcomes. In addition, given the sample
sizes available for drug trials in DMD, it will be important to
develop ways of incorporating knowledge gained from analyses
of natural history data into the analyses of drug effects.
The present study has important limitations. Although the
sample size and duration of follow-up is large for a DMD study,
the number of patients limited our ability to evaluate models
with more than 4 latent trajectory classes, more complex shapes
for mean trajectories within classes, more flexible models for
correlation over time, and non-normal error distributions. With
more participants, it may be possible to further describe the
trajectories and explain variation. It is possible that analyses of
larger sample sizes would identify more latent classes than the
four identified in the present study. Furthermore, the
reproducibility of these results should be explored, and new
studies are in progress to assess the reproducibility of trajectory
classes in separate DMD natural history databases.
5. Conclusions
The results of this preliminary study, designed as a proof of
concept, demonstrate that it is possible to reduce the high
variability of 3-year change in 6MWD in DMD patients by
approximately 40% over and above the 10–15% reduction
provided by baseline age, 6MWD and steroid use. If these
results are reproducible, latent class trajectory analysis may
enrich understanding of natural history in DMD and
complement other approaches to improving and accelerating
clinical trials of important therapeutic candidates.
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